As NLRP3 inhibition reduced COVID-19–like hyperinflammation and pathology in preclinical models, this has potential to treat severe SARS-CoV-2 complications (Diarimalala et al, 2023; Potere et al, 2023). The gene discussed is NLRP3; the disease is COVID-19.